Drawbacks in Current Rheumatoid Arthritis Therapies Point to a Large Untapped Market in the U.S., Finds Frost & Sullivan

Drawbacks in Current Rheumatoid Arthritis Therapies Point to a Large Untapped Market in the U.S., Finds Frost & Sullivan PR Newswire MOUNTAIN VIEW, California, Oct. 18, 2012 -- Emerging remedies must demonstrate a high degree of safety and efficacy to gain acceptance MOUNTAIN VIEW, California, Oct. 18, 2012 /PRNewswire/ -- The availability of tumor necrosis factor (TNF) inhibitors has greatly improved the pharmacological management of rheumatoid arthritis (RA). Both patients and physicians are familiar with TNF inhibitors due to their long history; however, their many limitations such as high cost, potential side effects, and injection requirement have created a need for alternative therapies. This need, along with a potentially large patient pool, is encouraging pharmaceutical and biotechnology companies with disease expertise to break into this sizeable market. New analysis from Frost & Sullivan's (http://www.lifesciences.frost.com) United States Market for Rheumatoid Arthritis Pharmacotherapeutics research finds that the market earned revenues of more than $7.74 billion in 2011 and estimates this to reach $11.79 billion in 2017. If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country. RA is an incurable chronic condition that affects 2.